Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer therapies. The company operates through dual R&D centers in the United States and mainland China, with its primary operating subsidiary in the PRC being Adlai Nortye Biopharma Co., Ltd. Its pipeline is concentrated in two key therapeutic areas: precision RAS pathway targeted therapies and next-generation PD-1/L1 pathway modulating immunotherapies. Key drug candidates include AN9025, an oral small-molecule pan-RAS(ON) inhibitor; AN4035, a CEACAM5-targeting antibody drug conjugate (ADC) built on the proprietary RASiCA platform; AN8025, a tri-functional fusion protein modulating T cells and antigen-presenting cells; AN4005, an oral small-molecule PD-L1 inhibitor; and AN0025, a small molecule EP4 antagonist. The company was originally incorporated in 2004 and transitioned to an R&D-driven model in 2016. It has partnered with Nucleai for digital pathology applications and lists on the Nasdaq under the symbol ANL.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage adlainortye.com
Sector Healthcare IR page ir.adlainortye.com
Tags
oncology, immuno-oncology, ras pathway inhibitors, antibody drug conjugates, pd-l1 inhibitors, small molecules, fusion proteins, clinical-stage, AN9025, AN4035, AN8025, AN4005, AN0025, RASiCA, Adlai Nortye Biopharma Co. Ltd., Adlai Nortye USA INC, Nucleai
Press page adlainortye.com/index.php

Metrics

Valuation  
Market cap $ 511.592M
Market cap (USD) $ 511.592M
P/E -14.41
PEG —
P/BV -61.47
P/S 102.32
P/OCF -15.29
P/FCF -15.21
Dividend yield —
Turnover / mcap —
Returns  
ROE 426.9%
ROI -218.5%
ROIC -164.7%
Profit margin -710.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 5M — 5M 0 45.726M
Net profit -35.528M -51.869M -104.871M -58.79M -56.678M
Free cash flow -33.639M -51.989M -56.852M -44.491M -4.154M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 1.42 2.36 8.85 — —
Price performance 12m -0.4 -0.73 — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 54.5M 58.2M 44.9M 32.8M
Reported Apr 19, 2024 Apr 19, 2024 Apr 30, 2025 Apr 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2026-10-27

PDF Version

AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona

Oral presentation will include translational and EGFR combination data for first-in-class AN4035

AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window

SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that an oral presentation on AN4035 will be shared during the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20 in Barcelona, Spain.

“We are delighted that an AN4035 abstract has been selected for an oral presentation at ENA for the second time,” said Dr. Archie Tse, President and Head of Research & Development at Adlai Nortye. “At this year’s meeting, we will share translational and combination data supporting the ongoing Phase I study of AN4035, including its evaluation with EGFR blockade. AN4035 is a first-in-class ADC targeting CEACAM5 armed with a proprietary pan-RAS(ON) inhibitor payload. By selectively delivering the payload to CEACAM5-expressing tumors, AN4035 is designed to broaden the therapeutic window and support combination with cetuximab. We look forward to discussing this important work with the oncology community and advancing the clinical development of AN4035.”

Oral Presentation Details

**Title:**Tumor-selective delivery of a pan-RAS(ON) inhibitor by the novel CEACAM5-targeted ADC AN4035 expands the therapeutic window and enables potent, well-tolerated combination with EGFR blockade Speaker: Archie Tse, MD, PhD, President, Head of R&D, Adlai Nortye Group Ltd. Date and Time: Thursday November 19, 8:00am Central European Time Session: Plenary Session 2 on “RAS pathway: “Targeting RAS – What’s Next?”” Location: Room 111 + 112

About AN4035

AN4035 is a first-in-class ADC targeting CEACAM5 and armed with a highly potent pan-RAS(ON) inhibitor payload. In preclinical studies, the ADC demonstrates favorable thermal and plasma stability with desirable pharmacokinetic properties. Strong intracellular payload retention drives nanomolar to picomolar cytotoxicity in CEACAM5-positive, RAS-addicted cancer cell lines, coupled with a potent bystander-killing effect. In vivo, AN4035 has shown robust anti-tumor activity with deep tumor regression in CEACAM5-positive CDX and PDX models. Compared with the payload alone, the ADC exhibits enhanced target-mediated tumor retention and significantly improved tumor selectivity over normal tissues, resulting in an overall favorable therapeutic index. Adlai Nortye is evaluating AN4035 in patients with CEACAM5-enriched RAS-addicted solid tumors in a global Phase I trial in Australia, U.S., and China.

About Adlai Nortye

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas:

  1. Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company's proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.

  2. Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells.

Forward-Looking and Cautionary Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company's preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company's therapeutic candidates; the Company's ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

2026-10-15

PDF Version

AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial

Cetuximab will be supplied by Lilly for the U.S. trial sites

Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites

SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced clinical trial collaboration and supply agreements (CTCSAs) with Eli Lilly and Company (“Lilly”) and Merck KGaA, Darmstadt, Germany for the anti-EGFR antibody cetuximab (marketed as ERBITUX®).

These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid tumors. Adlai Nortye is the sponsor of the trial. Lilly will supply cetuximab at no cost for the U.S. clinical trial sites. Merck KGaA, Darmstadt, Germany will supply cetuximab at no cost for the Australia and China clinical trial sites.

“We are pleased to enter clinical trial collaborations with both Lilly and Merck KGaA, Darmstadt, Germany to explore cetuximab in combination with AN4035, our first-in-class investigational ADC targeting CEACAM5 and armed with a highly potent pan-RAS(ON) inhibitor payload,” said Dr. Archie Tse, President, Head of Research & Development. “Dual inhibition of EGFR and RAS signaling is a compelling strategy for treating RAS-addicted cancers, but overlapping toxicities may limit systemic combinations. By selectively delivering a potent pan-RAS(ON) inhibitor to CEACAM5-expressing tumors through an ADC, AN4035 may broaden the therapeutic window for this rational combination with cetuximab. We are excited to evaluate this approach with participation by Lilly and Merck KGaA, Darmstadt, Germany in these patients with high unmet need.”

The ongoing global phase I trial is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors. CEACAM5 is highly overexpressed in colorectal, pancreatic, and lung cancers – tumor types that frequently harbor RAS mutations. The monotherapy and cetuximab combination arms will be initiated on a staggered start timeline.

About AN4035

AN4035 is a first-in-class ADC targeting CEACAM5 and armed with a highly potent pan-RAS(ON) inhibitor payload. In preclinical studies, the ADC demonstrates favorable thermal and plasma stability with desirable pharmacokinetic properties. Strong intracellular payload retention drives nanomolar to picomolar cytotoxicity in CEACAM5-positive, RAS-addicted cancer cell lines, coupled with a potent bystander-killing effect. In vivo, AN4035 has shown robust anti-tumor activity with deep tumor regression in CEACAM5-positive CDX and PDX models. Compared with the payload alone, the ADC exhibits enhanced target-mediated tumor retention and significantly improved tumor selectivity over normal tissues, resulting in an overall favorable therapeutic index. Adlai Nortye is evaluating AN4035 in a global phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors.

About Adlai Nortye

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas:

  1. Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company's proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.

  2. Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells.

Forward-Looking and Cautionary Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company's preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company's therapeutic candidates; the Company's ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

As previously reported by Adlai Nortye Group Ltd. (the “Company”), the Company held its Extraordinary General Meeting of shareholders (“EGM”) on September 30, 2026, at 10 a.m., Singapore time, at Meeting Room 35A, Level 35, The Gateway West, 150 Beach Road, Singapore 189720. Holders of a total of 40,433,365 ordinary shares, out of a total of 193,193,810 ordinary shares issued and outstanding and entitled to vote as of the record date of August 28, 2026, were present in person or by proxy at the EGM, constituting a quorum. All resolutions presented to the shareholders at its EGM were duly passed. Capitalized terms not otherwise defined in this report shall have the meanings assigned to them in the Company’s notice of the EGM dated August 26, 2026.

The full text of each resolution was included in the notice of the EGM, which was filed with the Securities and Exchange Commission on Form 6-K on August 26, 2026. The full text of the Form 6-K containing the resolutions is also available on the Company’s website, https://ir.adlainortye.com

1

Prompts

Adlai Nortye Group Ltd. (ticker ANL), listed in United States.

ETFs Holding Adlai Nortye Group Ltd.

ETF Weight in ETF Shares Market value As of
CANC 0.31% 46,444 $ 659.04K Aug 31, 2026